Jubilant Life Sciences to pump Rs 550 crore in capex in FY19Illustrative image – not actual.
Jubilant Life Sciences is planning to make an investment of Rs 550 crore in capital expenditure (capex) in the FY19 to meet the increased demand in its businesses.

The company is present across three major business segments namely pharmaceuticals, life science ingredients and drug discovery solutions.

In addition, the company also intends to invest Rs 300 crore in research and development (R&D) in FY19, including Rs 150 crore in product development expenditure.

In specialty pharmaceuticals, the company expects all its key verticals to deliver strong growth during FY19.

← All latest storiesBack to top →